Status:
RECRUITING
The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt
Lead Sponsor:
AstraZeneca
Conditions:
Atypical Hemolytic Uremic Syndrome
Eligibility:
All Genders
Brief Summary
Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases per million population per year. aHUS is...
Eligibility Criteria
Inclusion
- Male or female patients aged one month or older who have been diagnosed with TMA between 01-Jan-2010 and 31-Dec-2023.
Exclusion
- None. All records of patients with TMA will be screened for aHUS diagnosis.
Key Trial Info
Start Date :
October 13 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07218536
Start Date
October 13 2025
End Date
September 30 2026
Last Update
November 21 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Al Mansurah, Egypt
2
Research Site
Alexandria, Egypt
3
Research Site
Asyut, Egypt
4
Research Site
Cairo, Egypt